Autopsy report · NCT03999515
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Cause of deathSlow enrollment
“Terminated due to slow accrual”
Life of this trial
- Registered 10 months before it started.
- Ran for about 1 year 1 month before it stopped.
- 3 participants enrolled.
- Results were posted on the registry 2 years 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Conditions
- Castration-Resistant Prostate Carcinoma; Double-Negative Prostate Carcinoma; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate; Enzalutamide; Erdafitinib
- Participants
- 3
- Sites
- 1
- Countries
- United States
Trials that died the same way
- A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain
“Terminated due to low accrual” - Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
“Terminated due to poor accrual” - Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
“Terminated prematurely due to low accrual.” - Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
“Stopped due to slow accrual” - Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
“Terminated due to inadequate rate of accrual.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.